Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Trojan triplets: RNA-based pathomechanisms for muscle dysfunction in Huntington's disease.

Skov M, Dirksen RT.

J Gen Physiol. 2017 Jan;149(1):49-53. doi: 10.1085/jgp.201611728. Epub 2016 Dec 9. No abstract available.

2.

[Elucidation of molecular pathomechanisms of Huntington's disease].

Okazawa H.

Rinsho Shinkeigaku. 2012;52(2):63-72. Japanese.

PMID:
22354228
4.

Depressed Synaptic Transmission and Reduced Vesicle Release Sites in Huntington's Disease Neuromuscular Junctions.

Khedraki A, Reed EJ, Romer SH, Wang Q, Romine W, Rich MM, Talmadge RJ, Voss AA.

J Neurosci. 2017 Aug 23;37(34):8077-8091. doi: 10.1523/JNEUROSCI.0313-17.2017. Epub 2017 Jul 19.

5.

Muscle atrophy is associated with cervical spinal motoneuron loss in BACHD mouse model for Huntington's disease.

Valadão PA, de Aragão BC, Andrade JN, Magalhães-Gomes MP, Foureaux G, Joviano-Santos JV, Nogueira JC, Ribeiro FM, Tapia JC, Guatimosim C.

Eur J Neurosci. 2017 Mar;45(6):785-796. doi: 10.1111/ejn.13510. Epub 2017 Jan 30.

PMID:
27992085
6.

Progressive Cl- channel defects reveal disrupted skeletal muscle maturation in R6/2 Huntington's mice.

Miranda DR, Wong M, Romer SH, McKee C, Garza-Vasquez G, Medina AC, Bahn V, Steele AD, Talmadge RJ, Voss AA.

J Gen Physiol. 2017 Jan;149(1):55-74. doi: 10.1085/jgp.201611603. Epub 2016 Nov 29.

7.

Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation.

Ribchester RR, Thomson D, Wood NI, Hinks T, Gillingwater TH, Wishart TM, Court FA, Morton AJ.

Eur J Neurosci. 2004 Dec;20(11):3092-114.

PMID:
15579164
8.

Body composition analysis as an indirect marker of skeletal muscle mass in Huntington's disease.

Cubo E, Rivadeneyra J, Gil-Polo C, Armesto D, Mateos A, Mariscal-Pérez N.

J Neurol Sci. 2015 Nov 15;358(1-2):335-8. doi: 10.1016/j.jns.2015.09.351. Epub 2015 Sep 15.

PMID:
26394908
9.

Bimanual co-ordination in Huntington's disease.

Johnson KA, Bennett JE, Georgiou N, Bradshaw JL, Chiu E, Cunnington R, Iansek R.

Exp Brain Res. 2000 Oct;134(4):483-9.

PMID:
11081830
10.

Gene expression in Huntington's disease skeletal muscle: a potential biomarker.

Strand AD, Aragaki AK, Shaw D, Bird T, Holton J, Turner C, Tapscott SJ, Tabrizi SJ, Schapira AH, Kooperberg C, Olson JM.

Hum Mol Genet. 2005 Jul 1;14(13):1863-76. Epub 2005 May 11.

PMID:
15888475
11.

Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease.

Martin B, Golden E, Carlson OD, Pistell P, Zhou J, Kim W, Frank BP, Thomas S, Chadwick WA, Greig NH, Bates GP, Sathasivam K, Bernier M, Maudsley S, Mattson MP, Egan JM.

Diabetes. 2009 Feb;58(2):318-28. doi: 10.2337/db08-0799. Epub 2008 Nov 4.

12.

Skeletal muscle characteristics and mitochondrial function in Huntington's disease patients.

Gehrig SM, Petersen JA, Frese S, Mueller SM, Mihaylova V, Ligon-Auer M, Lundby C, Toigo M, Jung HH.

Mov Disord. 2017 Aug;32(8):1258-1259. doi: 10.1002/mds.27031. Epub 2017 Jun 16. No abstract available.

PMID:
28620963
13.

Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice.

Pang TY, Stam NC, Nithianantharajah J, Howard ML, Hannan AJ.

Neuroscience. 2006 Aug 25;141(2):569-84. Epub 2006 May 22.

PMID:
16716524
14.

Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.

Liu W, Chaurette J, Pfister EL, Kennington LA, Chase KO, Bullock J, Vonsattel JP, Faull RL, Macdonald D, DiFiglia M, Zamore PD, Aronin N.

J Huntingtons Dis. 2013;2(4):491-500. doi: 10.3233/JHD-130079.

PMID:
25062733
15.

Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse.

Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AH.

Ann Neurol. 2000 Jan;47(1):80-6.

PMID:
10632104
16.

Decreased neuronal nitric oxide synthase messenger RNA and somatostatin messenger RNA in the striatum of Huntington's disease.

Norris PJ, Waldvogel HJ, Faull RL, Love DR, Emson PC.

Neuroscience. 1996 Jun;72(4):1037-47.

PMID:
8735228
17.

Impaired PGC-1alpha function in muscle in Huntington's disease.

Chaturvedi RK, Adhihetty P, Shukla S, Hennessy T, Calingasan N, Yang L, Starkov A, Kiaei M, Cannella M, Sassone J, Ciammola A, Squitieri F, Beal MF.

Hum Mol Genet. 2009 Aug 15;18(16):3048-65. doi: 10.1093/hmg/ddp243. Epub 2009 May 21.

18.

Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington's disease.

She P, Zhang Z, Marchionini D, Diaz WC, Jetton TJ, Kimball SR, Vary TC, Lang CH, Lynch CJ.

Am J Physiol Endocrinol Metab. 2011 Jul;301(1):E49-61. doi: 10.1152/ajpendo.00630.2010. Epub 2011 Apr 19.

19.

Exercise training normalizes mitochondrial respiratory capacity within the striatum of the R6/1 model of Huntington's disease.

Herbst EA, Holloway GP.

Neuroscience. 2015 Sep 10;303:515-23. doi: 10.1016/j.neuroscience.2015.07.025. Epub 2015 Jul 14.

PMID:
26186895
20.

Motor phenotype is not associated with vascular dysfunction in symptomatic Huntington's disease transgenic R6/2 (160 CAG) mice.

Di Pardo A, Carrizzo A, Damato A, Castaldo S, Amico E, Capocci L, Ambrosio M, Pompeo F, De Sanctis C, Spinelli CC, Puca AA, Remondelli P, Maglione V, Vecchione C.

Sci Rep. 2017 Feb 17;7:42797. doi: 10.1038/srep42797.

Supplemental Content

Support Center